Biotech · Public company · Danbury, CT, US
Mannkind Corp
Ticker MNKD · SEC CIK 0000899460
Track this companyFree. Adds Mannkind Corp to your Dealase workspace and tells you when its record changes.
Clinical trials152 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline16
- AfrezzaPhase 3 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Basal InsulinPhase 3 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Clofazimine Inhalation SuspensionPhase 3 · MAC Lung DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Rapid-acting Insulin AnalogPhase 3 · Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- AfrezzaPhase 2 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Basal insulinPhase 2 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- Technosphere InsulinPhase 2 · Type 1 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- (Part A) MKND-201Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- (Part B) MKND-201Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- MNKD-201(Nintedanib DPI)Phase 1 · Idiopathic Pulmonary Fibrosis (IPF)ClinicalTrials.gov · fetched Nov 12, 2026
- Afrezza (insulin human) Inhalation PowderType 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- Afrezza Dose 1Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Afrezza Dose 2Diabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)Type 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- insulin degludecType 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- insulin degludecDiabetes Mellitus, Type 1ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesPHASE2 · RECRUITING · started Feb 4, 2026ClinicalTrials.gov NCT07224321 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary FibrosisPHASE1 · COMPLETED · started Dec 22, 2025ClinicalTrials.gov NCT07344558 · fetched Nov 12, 2026
- Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin DeliveryNA · RECRUITING · started Jun 5, 2025ClinicalTrials.gov NCT06880835 · fetched Nov 12, 2026
- Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational DiabetesPHASE2_PHASE3 · COMPLETED · started Jun 2, 2025ClinicalTrials.gov NCT06535789 · fetched Nov 12, 2026
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionPHASE3 · TERMINATED · started Sep 11, 2024ClinicalTrials.gov NCT06418711 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy VolunteersPHASE1 · UNKNOWN · started May 28, 2024ClinicalTrials.gov NCT06532942 · fetched Nov 12, 2026
- INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 DiabetesPHASE4 · COMPLETED · started Jul 7, 2023ClinicalTrials.gov NCT05904743 · fetched Nov 12, 2026
- Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 DiabetesPHASE4 · COMPLETED · started Mar 31, 2022ClinicalTrials.gov NCT05243628 · fetched Nov 12, 2026
- Afrezza® INHALE-1 Study in PediatricsPHASE3 · COMPLETED · started Sep 29, 2021ClinicalTrials.gov NCT04974528 · fetched Nov 12, 2026
- Afrezza® Dosing Optimization StudyPHASE4 · COMPLETED · started Apr 9, 2021ClinicalTrials.gov NCT04849845 · fetched Nov 12, 2026
- A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily InjectionsPHASE4 · UNKNOWN · started Feb 27, 2019ClinicalTrials.gov NCT04125082 · fetched Nov 12, 2026
- Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes PatientsPHASE3 · COMPLETED · started Oct 16, 2017ClinicalTrials.gov NCT03324776 · fetched Nov 12, 2026
- A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium AlonePHASE4 · UNKNOWN · started Oct 5, 2017ClinicalTrials.gov NCT03313960 · fetched Nov 12, 2026
- Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT StudyPHASE4 · COMPLETED · started Sep 30, 2017ClinicalTrials.gov NCT03143816 · fetched Nov 12, 2026
- Afrezza Safety and Pharmacokinetics Study in Pediatric PatientsPHASE2 · COMPLETED · started Sep 28, 2017ClinicalTrials.gov NCT02527265 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 21, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026